The effect of acute and 14-day exogenous ketone supplementation on glycemic control in adults with type 2 diabetes: two randomized controlled trials

• Published in: American journal of physiology: endocrinology and metabolism Vol. 326; no. 1; pp. E61 - E72
• Main Authors: Falkenhain, Kaja, Oliveira, Barbara F, Islam, Hashim, Neudorf, Helena, Cen, Haoning H, Johnson, James D, Madden, Kenneth, Singer, Joel, Walsh, Jeremy J, Little, Jonathan P
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.01.2024
• Subjects: Adults; Amino acids; Blood; Blood glucose; Body mass; Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); Fatty acids; Glucose; Glucose metabolism; Ingestion; Insulin; Ketones; Metabolomics; Supplements; glycemia; glucose control; ketosis; type 2 diabetes; metabolomics
• ISSN: 0193-1849; 1522-1555
• DOI: 10.1152/ajpendo.00332.2023

Acute ingestion of the exogenous ketone monoester supplement [(R)-3-hydroxybutyl-(R)-3-hydroxybutyrate] lowers blood glucose, suggesting therapeutic potential in individuals with impaired glucose metabolism. However, it is unknown how acute or repeated ingestion of exogenous ketones affects blood glucose control in individuals with type 2 diabetes (T2D). We conducted two randomized, counterbalanced, double-blind, placebo-controlled crossover trials to determine if ) acute exogenous ketone monoester (0.3 g/kg body mass; = 18) or ) 14-day thrice daily premeal exogenous ketone monoester (15 g; = 15) supplementation could lower blood glucose in individuals living with T2D. A single dose of the ketone monoester supplement elevated blood β-OHB to ∼2 mM. There were no differences in the primary outcomes of plasma glucose concentration (acutely) or serum fructosamine (glycemic control across 14 days) between conditions. Ketone monoester ingestion acutely increased insulin and lowered nonesterified fatty acid concentrations; plasma metabolomics confirmed a reduction in multiple free fatty acids species and select gluconeogenic amino acids. In contrast, no changes were observed in fasting metabolic outcomes following 14 days of supplementation. In the context of these randomized controlled trials, acute or repeated ketone monoester ingestion in adults with T2D did not lower blood glucose when consumed acutely in a fasted state and did not improve glycemic control following thrice daily premeal ingestion across 14 days. Future studies exploring the mechanistic basis for the (lack of) glucose-lowering effect of exogenous ketone supplementation in T2D and other populations are warranted. Exogenous ketone supplements can acutely lower blood glucose, suggesting therapeutic potential in individuals with impaired glucose metabolism. However, the effect of exogenous ketones on glucose metabolism in adults with type 2 diabetes has not been investigated in a controlled setting. In adults with type 2 diabetes, ketone monoester ingestion did not lower blood glucose acutely in a fasted state and did not improve glycemic control across thrice daily premeal ingestion across 14 days.